lazertinib: Clinical Trials

36 trials of lazertinib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

11 completed, 10 active not recruiting, 7 unknown, 6 recruiting. 21 Phase 2, 8 Phase 1, 4 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 221Recruiting 6, Active not recruiting 5, Unknown 5, Completed 4, Terminated 1
Phase 18Completed 6, Active not recruiting 2
Phase 34Active not recruiting 3, Completed 1

Follow lazertinib: new trials by email Literature Review of lazertinib trials Research Report on lazertinib

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
Amivantamab, Lazertinib, Carboplatin - Carcinoma, Non-Small-Cell Lung
Phase 2RecruitingJanssen Research & Development, LLC682026-07-282026-11-03
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Amivantamab, Lazertinib, Chemotherapy: Pemetrexed - Carcinoma, Non-Small-Cell Lung
Phase 2RecruitingJanssen Research & Development, LLC4802024-12-162026-11-03
Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment
Lazertinib, Tepotinib - Non-Small Cell Lung Cancer Metastatic
Phase 2RecruitingSehhoon Park472024-06-112026-09-10
Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
Amivantamab IV, Amivantamab SC, Lazertinib - Carcinoma, Non-Small-Cell Lung
Phase 2Active not recruitingJanssen Research & Development, LLC3052024-02-162026-11-03
A Randomized Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & Smoker
Lazertinib, Bevacizumab Injectable Product - Lazertinib
Phase 2RecruitingNational Cancer Center, Korea1202023-09-052023-12-05
Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy
Lazertinib+Pemetrexed+Carboplatin, Lazertinib - Non Small Cell Lung Cancer
Phase 2UnknownYonsei University1292023-09-012023-09-01
A Study of Lazertinib (JNJ-73841937) Tablet in Healthy Adult Participants
Lazertinib - Healthy
Phase 1CompletedJanssen Research & Development, LLC722023-05-302025-02-03
Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor Mutations
Amivantamab, Lazertinib, Pemetrexed 500 mg - Metastatic Non-small Cell Lung Cancers
Phase 2CompletedLatin American Cooperative Oncology Group542023-05-242026-08-28
Premedication to Reduce Amivantamab Associated Infusion Related Reactions
Dexamethasone, Montelukast, Methotrexate - Carcinoma, Non-Small-Cell Lung
Phase 2Active not recruitingJanssen Research & Development, LLC682023-05-182026-11-03
Lazertinib+Pemetrexed/Carboplatin in Patients With EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to Prior Lazertinib
Lazertinib/Pemetrexed/Carboplatin - Non-small Cell Lung Cancer
Phase 2CompletedYonsei University652023-04-072026-10-07
Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI
Amivantamab, Lazertinib, Zirabev - Non Small Cell Lung Cancer
Phase 2Active not recruitingETOP IBCSG Partners Foundation602023-03-272026-11-12
Impact of Lazertinib Dose Modification on Effectiveness and Safety
Lazertinib - Non-small Cell Lung Cancer
UnknownPusan National University Hospital2002023-02-012023-02-08
Lazertinib 160mg in EGFR T790M NSCLC
Lazertinib - Lung Cancer Stage IV, EGFR T790M
Phase 2UnknownSamsung Medical Center1172023-02-012023-01-27
To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation
Vabametkib, Lazertinib - Advanced Solid Tumors
Phase 2RecruitingAbion Inc1782023-01-172025-05-22
Lazertinib for NSCLC Harboring Activating EGFR Mutations in TKI naïve Patients
Lazertinib group - NSCLC
Phase 2Active not recruitingSehhoon Park1502023-01-042026-07-28
A Study of Four Different Oral Tablet Formulations of Lazertinib (JNJ-73841937) in Healthy Adult Participants
Lazertinib - Healthy
Phase 1CompletedJanssen Research & Development, LLC642023-01-032023-06-02
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Amivantamab, Lazertinib, Carboplatin - Carcinoma, Non-small-Cell Lung
Phase 2RecruitingJanssen Research & Development, LLC5202022-11-112026-11-03
Lazertinib/Pemetrexed/Carboplatin After Osimertinib Failure in NSCLC With Brain Metastases
Lazertinib, Pemetrexed, Carboplatin - Non-small Cell Lung Cancer
Phase 2TerminatedJin Hyoung Kang142022-08-122026-10-08
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
Lazertinib, Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF), Amivantamab Intravenous - Advanced or Metastatic Non-small Cell Lung Cancer
Phase 3Active not recruitingJanssen Research & Development, LLC4182022-08-052026-11-03
Lazertinib Real-world Observational Study of in Pre-treated EGFR T790M Mutant With Advanced Non-small Cell Lung Cancer
Lazertinib - Metastatic Lung Non-Small Cell Carcinoma, EGFR T790M
UnknownSamsung Medical Center9002022-07-312022-05-19

Showing 20 of 36. Sign in to see all of them.

Conditions studied

Carcinoma, Non-Small-Cell Lung (23)  ·  Lung Neoplasms (2)  ·  Adenocarcinoma of Lung (1)

Sponsors

Janssen Research & Development, LLC (16)  ·  Yonsei University (5)  ·  Yuhan Corporation (3)  ·  Samsung Medical Center (2)  ·  Sehhoon Park (2)  ·  Abion Inc (1)  ·  ETOP IBCSG Partners Foundation (1)  ·  Jin Hyoung Kang (1)  ·  Latin American Cooperative Oncology Group (1)  ·  Memorial Sloan Kettering Cancer Center (1)  ·  National Cancer Center, Korea (1)  ·  Pusan National University Hospital (1)  ·  Sung Yong Lee (1)

Countries

South Korea (24)  ·  United States (16)  ·  Spain (12)  ·  France (10)  ·  Taiwan (10)  ·  China (8)  ·  Germany (8)  ·  United Kingdom (8)  ·  Italy (7)  ·  Brazil (6)  ·  Japan (6)  ·  Malaysia (6)  ·  Canada (5)  ·  Israel (5)  ·  Turkey (Türkiye) (5)

Top investigators

Hye Ryun Kim (2)  ·  Helena Yu, MD (1)  ·  Jin Hyoung Kang (1)  ·  Jin Seok Ahn, MD, PhD (1)  ·  Min Ki Lee, MD, PhD (1)  ·  MinHee Hong (1)  ·  Ross Soo, MD FRACP (1)  ·  Sehhoon Park (1)  ·  Sehhoon Park, MD (1)  ·  Sun Min Lim (1)  ·  Sung Yong Lee, MD, PhD (1)

Results publications

PMID 34339261, PMID 34339292, PMID 34911336, PMID 35962934, PMID 35963523, PMID 36002368, PMID 36268845, PMID 36652175, PMID 37022784, PMID 37379502, PMID 37589131, PMID 37710001, PMID 37865896, PMID 38476120, PMID 38857463, PMID 38924756, PMID 39033692, PMID 39755170, PMID 39864547, PMID 39918363, PMID 40350080, PMID 40383434, PMID 40617394, PMID 40923797, PMID 40923969, PMID 41139066, PMID 41259729, PMID 41927036, PMID 42635093, PMID 42833236, PMID 42870814

NIH funding

2023 (6), 2018 (1), 2019 (1), 2025 (1)